Fluicell launches Biopixlar AER for compact single-cell bioprinting »

Swedish bioprinting firm Fluicell launched its second single-cell 3D bioprinter: the brand new Biopixlar AER is a compact 3D bioprinter that lets customers create detailed organic tissues with excessive precision. It’s the world’s first microfluidic high-precision bioprinter that matches inside a typical circulate hood or biosafety cupboard. Fluicell designed it for prime automation and simple workflow integration, with the purpose of bringing Biopixlar expertise to new buyer segments.

Biopixlar AER brings the identical high-resolution Biopixlar bioprinting expertise with single-cell decision that the Firm’s prospects are used to, however in a compact and moveable format that meets market demand for customizable platforms, tailor-made to at present’s laboratory surroundings.

“With Biopixlar AER, now we have reached a brand new vital milestone and we will now supply a pioneering product, totally tailor-made to fulfill present and future wants within the quickly accelerating life science and analysis sector,” stated CEO Victoire Viannay. “Biopixlar AER has been developed by Fluicell’s R&D division underneath the management of CTO Gavin Jeffries and is a results of our focused innovation-work specializing in the need amongst researchers for compact and simply built-in bioprinting platform that may supply the identical excessive decision as our different Biopixlar® devices. With this new platform inside the Biopixlar® household, we now have a product vary that may meet future wants in healthcare and on the identical time lets us goal new and thrilling buyer segments.”

Fluicell has developed Biopixlar AER in step with the Firm’s long-term technique to push the boundaries of what’s potential in medical analysis and drug growth by combining high-performance bioprinting with flexibility and flexibility. The instrument comes geared up with a number of user-friendly options that make it straightforward to combine in laboratory workflows together with different organic and medical practices. The mixture of compactness, ease of use and distant management makes the platform enticing to be used in demanding environments, for instance within the area business and in deep-sea analysis.

As a part of the event work, the efficiency and person expertise of Biopixlar AER has been examined in analysis laboratories at Karolinska Institutet, amongst others.

Oscar Jungholm, Joseph Bruton and Kent Jardemark of the Division of Physiology and Pharmacology, at Karolinska Institutet collectively acknowledged that they “take into account Biopixlar AER to be a very exceptional innovation, which is straightforward to put in and deal with by way of its multi-modal management system. This novel platform allows a broad spectrum of latest experimental approaches, similar to research of molecular uptake into cells, superior electrophysiological recordings by way of calcium-imaging, and research of cell communication and signaling. Certainly, the Biopixlar AER can be nicely tailored for exact or native administration of medicine to cells, enabling superior pharmacological research.”